Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial

Autor: Sibylle Boehmer, Lars Franzén, Robert E. Coleman, Joe M. O'Sullivan, Rui Li, Steffen Wedel, Isabel Syndikus, John P Logue, Mihalj Seke, David Bottomley, Ales Chodacki, Oliver Sartor, Daniel Heinrich, Sophie D. Fosså, Nicholas D. James, Marcos F. Dall'Oglio, Paweł Wiechno, K. Staudacher, Sten Nilsson, Peter Hoskin, Arne Solberg, Nicholas J. Vogelzang, Oana Petrenciuc, Svein Inge Helle, Anders Widmark, Ján Kliment, Øyvind S. Bruland, Dag Clement Johannessen, Chris Parker

Publikováno v: Parker, C C, Coleman, R E, Sartor, O, Vogelzang, N J, Bottomley, D, Heinrich, D, Helle, S I, O'Sullivan, J M, Fosså, S D, Chodacki, A, Wiechno, P, Logue, J, Seke, M, Widmark, A, Johannessen, D C, Hoskin, P, James, N D, Solberg, A, Syndikus, I, Kliment, J, Wedel, S, Boehmer, S, Dall'Oglio, M, Franzén, L, Bruland, Ø S, Petrenciuc, O, Staudacher, K, Li, R & Nilsson, S 2017, ' Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial ', European Urology, vol. 73, pp. 427-435 . https://doi.org/10.1016/j.eururo.2017.06.021
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Translational Andrology and Urology
Parker, C C, Coleman, R E, Sartor, O, Vogelzang, N J, Bottomley, D, Heinrich, D, Helle, S I, O'Sullivan, J M, Fosså, S D, Chodacki, A, Wiechno, P, Logue, J, Seke, M, Widmark, A, Johannessen, D C, Hoskin, P, James, N D, Solberg, A, Syndikus, I, Kliment, J, Wedel, S, Boehmer, S, Dall'Oglio, M, Franzén, L, Bruland, Ø S, Petrenciuc, O, Staudacher, K, Li, R & Nilsson, S 2017, ' Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial ', European Urology . https://doi.org/10.1016/j.eururo.2017.06.021

BACKGROUND: In Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 versus placebo prolonged overall survival with favorable safety in castration-resistant prostate cancer patients with symptomatic bone metastases. Long-term radium-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e18d23aabdbd329a4ac3ee0a9d5e41fe
https://doi.org/10.1016/j.eururo.2017.06.021

Integraler baulicher Erdbebenschutz IV: Räumlich schwimmende Lagerung und SEISMISCHE-MASSE-ANALOGIE

Autor: K. Staudacher, Räumlich

Integraler baulicher Erdbebenschutz I: Schutzauftrag — Begriffe — rechnerischer Nachweis

Autor: K. Staudacher

MP70-10 FURTHER CHARACTERIZATION OF THE EFFECTS OF PRIOR OR NO PRIOR DOCETAXEL THERAPY ON CRPC PATIENTS WITH BONE METASTASES RECEIVING RA-223 IN THE PHASE 3 ALSYMPCA TRIAL

Autor: Sten Nilsson, Neal D. Shore, Peter Hoskin, K. Staudacher, Oliver Sartor, Mona Wahba, Chris Parker, Nicholas J. Vogelzang, Robert E. Coleman

Publikováno v: Journal of Urology. 191

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::232221c3cd5dac4802d2e96592317d34
https://doi.org/10.1016/j.juro.2014.02.2209

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.